Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.
Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, Bogdan S, Huang M, Fisher GA, Park S, Lee SH, Hwang JE, Chung JH, Kim L, Song H, Pereira S, Shin S, Lim Y, Ahn CH, Kim S, Oum C, Kim S, Park G, Song S, Jung W, Kim S, Bang YJ, Mok TSK, Ali SM, Ock CY. Shen J, et al. Among authors: kim h, kim s, kim l. J Immunother Cancer. 2024 Feb 14;12(2):e008339. doi: 10.1136/jitc-2023-008339. J Immunother Cancer. 2024. PMID: 38355279 Free PMC article.
Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy.
Lee D, Park J, Choi H, Gim G, Cho S, Kim L, Oh Y, Kang CY, Kim Y, Tan D, de Viveiros PAH, Chae YK. Lee D, et al. Among authors: kim y, kim l. Heliyon. 2021 Sep 2;7(9):e07916. doi: 10.1016/j.heliyon.2021.e07916. eCollection 2021 Sep. Heliyon. 2021. PMID: 34568594 Free PMC article.
Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.
Kang CY, Duarte SE, Kim HS, Kim E, Park J, Lee AD, Kim Y, Kim L, Cho S, Oh Y, Gim G, Park I, Lee D, Abazeed M, Velichko YS, Chae YK. Kang CY, et al. Among authors: kim e, kim hs, kim y, kim l. Oncologist. 2022 Jun 8;27(6):e471-e483. doi: 10.1093/oncolo/oyac036. Oncologist. 2022. PMID: 35348765 Free PMC article. Review.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, Viscardi G, Ferrara R, Veronesi G, Forde PM, Taube J, Vokes E, Bestvina CM, Dolezal JM, Sacco M, Monteforte M, Cascone T, Garassino MC, Torri V. Hines JB, et al. Among authors: kim l. J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117-5. doi: 10.1016/j.jtho.2024.03.010. Online ahead of print. J Thorac Oncol. 2024. PMID: 38461929 Free article.
2,595 results